What is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob
|
|
- Jordan Daniels
- 6 years ago
- Views:
Transcription
1 Presenter Disclosure Information 5 6pm Nonalcoholic Fatty Liver Disease (NAFLD): Another Obesity-Related Epidemic SPEAKER Elliot Tapper, MD The following relationships exist related to this presentation: Dr Tapper had no financial relationships to disclose. Off-Label/Investigational Discussion In accordance with pmicme policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations. Learning Objectives Case 1: Rob Identify the risk factors for and disease spectrum of non-alcoholic fatty liver disease (NAFLD) Apply the latest evidence-based recommendations for the management of NAFLD Understand the indications for liver biopsy and further investigation 42-year-old white male BMI: 29 kg/m 2 Drinks socially Fasting LDL: 160 mg/dl Fasting glucose: 113 mg/dl ALT level: 90 IU/L Viral hepatitis screen: negative ALT=alanine aminotransferase Questions Pertinent to Rob Does he have NAFLD? Should he be concerned? How should he be worked up? Should he stop drinking alcohol completely? Does he need a referral to GI? Does he need a liver biopsy? Is it safe to consider statins to lower his LDL? What is NAFLD?.?
2 Spectrum of NAFLD: NAFL vs. Spectrum of NAFLD NAFL Simple fatty liver Histologically characterized by macrovesicular steatosis with no additional pathology. Generally considered benign from a hepatic standpoint. Histologically advanced fatty liver. Characterized by steatosis, inflammation, ballooning, fibrosis. Can lead to cirrhosis and liver failure. Normal Steatosis (NAFL) Steatohepatitis () Fibrosis/ cirrhosis NAFLD=nonalcoholic fatty liver disease =nonalcoholic steatohepatitis Risk Factors for NAFLD Major Co-Morbidities Type 2 diabetes Dyslipidemia Obesity Metabolic syndrome Hyperuricemia Emerging Associations Hypothyroidism Sleep apnea Hypopituitarism Hypogonadism Polycystic ovary syndrome Racial Differences in Fatty Liver Disease Prevalence of steatosis ( 1 H-MR Spect) in 2971 multiethnic adults in the Dallas Heart Study 100% Compared to Caucasians, NAFLD is less common among African-Americans 80% and more common among Hispanics 60% and cryptogenic 45% cirrhosis are less common 40% 31% 33% among African-Americans 24% 20% 0% All Hispanic White Black * Blacks had comparable obesity, diabetes, hyper TG, and low HDL. Lonardo A, et al. J Hepatol. 2006; 44: Vuppalanchi R, Chalasani N. Hepatology. 2009;49: Adapted from Browning JD, et al. Hepatology. 2004;40(6): The Two Hit Model: Day & James (1998) The One Hit Theory Normal first hit Steatosis Obesity Insulin resistance Normal Hepatitis+ Fibrosis Oxidative Stress Cytokines Steatosis FFA/Glu/Insulin Oxidative stress ER stress Cytokine stress??? Cell death Inflammation Fibrosis Adapted from Day CP & James OFW. Gastroenterology. 1998:114:
3 Hepatic Outcomes of NAFLD Should Rob be concerned? Simple Steatosis Cirrhosis Cryptogenic Cirrhosis Largely benign with minimal risk of cirrhosis Progressive with 20% risk of cirrhosis over a 10-yr time horizon Moderate risk for liver cancer (2-4% per year) Likely a burnt-out form of in up to 80% of patients Outcomes in NAFLD Outcomes Overall Mortality Incident CVD Incident Type 2 Diabetes Surrogates NAFLD vs. general population ALT as a surrogate GGT as a surrogate Imaging as a surrogate ALT as a surrogate GGT as a surrogate Imaging as a surrogate OR=odds ratio 95% CI= 95% confidence interval ALT =alanine aminotransferase Musso G, et al. Ann Med. 2011;43(6): # Studies OR [95% CI] 8 studies 1.57 [ ] 6 studies 10 studies 7 studies 17 studies 12 studies 3 studies 1.10 [ ] 1.57 [ ] 2.05 [ ] 1.97 [ ] 2.74 [ ] 3.51 [ ] CVD=cardiovascular disease GGT= γ-glutamyl transferase vs. NAFL Meta-analysis Outcomes # studies OR [95% CI] Overall mortality 5 studies 1.81 [ ] Liver-related mortality CVD-related mortality OR=odds ratio for vs steatosis 95% CI= 95% confidence interval Musso G, et al. Ann Med. 2011;43(6): studies 5.71 [ ] 5 Studies 0.91 [ ] Key Elements in the Diagnosis How do we evaluate Rob to provide him with an accurate diagnosis? NAFLD No significant alcohol consumption No competing etiologies (eg, autoimmune, HCV, etc), or medications (eg, amiodarone, tamoxifen) Imaging evidence of hepatic steatosis Aminotransferases may or may not be elevated However, only a liver biopsy can establish the presence of
4 Diagnosis of NAFLD/ Work-Up of Patients with NAFLD Aminotransferases Imaging tests Can be normal in patients with NAFLD and even Currently not able to establish the presence of Meticulous alcohol and medication history Exclusion of co-existing or competing etiologies Auto-antibodies and hyperferritinemia are common Fasting lipid profile and measures of insulin resistance Imaging to establish the presence of steatosis Liver biopsy to establish the presence of NOTE: The upper limits of normal for liver enzymes vary across different laboratories and do not determine the health of your patient s liver Mofrad P, et al. Hepatology. 2003; 37: When to Biopsy? Surrogate Markers/Predictive Models Patients with NAFLD at increased risk for steatohepatitis and advanced fibrosis. Presence of metabolic syndrome and the NAFLD Fibrosis Score may be used to identify patients at risk for steatohepatitis and advanced fibrosis. Consider Liver Biopsy for Patients with suspected NAFLD in whom competing etiologies for hepatic steatosis and co-existing chronic liver diseases cannot be excluded without a liver biopsy. Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease. AASLD, AGA, ACG Practice Guideline. Hepatology Jun;55(6): Predict Adapted from Musso G, et al. Ann Med. 2011;43(6): Predict Advanced Fibrosis Metabolic Syndrome CK-18 fragments NAFLD Fibrosis Score CK-18 + sfas Transient elastography Oxidized Fatty acids Fibrotest test BARD score Predictive Index ELF panel Obesity NAFLD score Fibrometer Clinical Score Genomics NAFIC (ferritin, insulin, collagen) IU panel MR elastography CK=Cytokeratin; sfas=soluble FAS; ELF=European Liver Fibrosis Panel; MR=magnetic resonance; BARD=Body-mass index, AST/ALT Ratio, Diabetes (type 2) NAFLD Fibrosis Score (NFS) Transient Elastography NAFLD Fibrosis Score predicts long-term outcomes in individuals with NAFLD Independent predicts advanced fibrosis. Based on six variables: age, BMI, AST/ALT ratio, hyperglycemia/diabetes, platelet count and albumin Noninvasive Safe, Reliable FDA Approved in 2013 Risk Score Calculation * age (years) * BMI (kg/m 2 ) * IFG/diabetes (yes=1, no=0) * AST/ALT ratio * platelet (x10 9 /l) * albumin (g/dl) Detects cirrhosis with 99% NPV and 46% PPV PPV and NPV = positive and negative predictive value. Angulo P, et al. Hepatology. 2007;45: /Kim D, et al. Hepatology. 2013;57: ;. Angulo P, et al. Gastroenterology. 2013: in press. Tapper EB, Castera L, Afdhal NH. Clinical Gastroenterology and Hepatology. 2014: in press.
5 How do we use these new tests and when is referral to GI indicated? Now that Rob has a diagnosis, what do are we going to do for him? Treating a Patient with NAFLD Treatment* of Liver Disease in NAFLD If a patient has, attention should be paid to metabolic co-morbidities as well as liver disease However, if a patient has steatosis alone, attention should be paid to metabolic and cardiovascular morbidities Potential Options: Life style modification Bariatric surgery Vitamin E Insulin sensitizers Tested But Do Not Work: UDCA (Ursodiol) Metformin Under Investigation: Pentoxifylline Obeticholic acid Eicosapentaenoic acid Many others *No agents are approved for treating NAFLD/ UDCA=ursodeoxycholic acid Lifestyle Modification for NAFLD Bariatric Surgery* Weight Loss At least 3-5% necessary to improve steatosis Weight loss up to 10% may be needed to improve necroinflammation + Generally reduces hepatic steatosis Achieved either by hypocaloric diet alone or in with increased physical activity. Evidence: A Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease. AASLD, AGA, ACG Practice Guideline. Hepatology Jun;55(6): Exercise Exercise alone in adults may reduce hepatic steatosis Ability to improve other aspects of liver histology remains unknown. BUT no good data available on specific diets that are most effective. Bariatric surgery improves steatosis and may improve necroinflammation (and possibly fibrosis) in carefully selected patients Meta-analysis by Mummadi et al. showed that steatosis, steatohepatitis, and fibrosis improve following bariatric surgery However, Cochrane review highlights lack of welldesigned studies *Not indicated as a treatment for NAFLD/ Mummadi RR, et al. Clin Gastroenterol Hepatol. 2008;6: Chavez-Tapia NC, et al. Cochrane Database of Syst Rev Jan 20;(1):CD
6 Bariatric Surgery in NAFLD/ Insulin Sensitizers* for Not contraindicated in otherwise eligible obese persons with NAFLD or (without established cirrhosis) Evidence: A Foregut Bariatric Surgery Type, safety and efficacy of this surgery in otherwise eligible obese persons with established cirrhosis due to NAFLD are not established. Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease. AASLD, AGA, ACG Practice Guideline. Hepatology Jun;55(6): Premature to consider foregut bariatric surgery as established option to specifically treat Metformin Thiazolidinediones Rosiglitazone Pioglitazone *Not approved as a treatment for NAFLD/ No role in either adults or children Improve liver histology but weight gain is a problem Unavailable Role is unclear. Improves histology in non-diabetics with, but is not approved in non-diabetics. Concerns of unfavorable safety Multisociety Practice Guideline: Pioglitazone* & Pioglitazone can be used to treat steatohepatitis in patients with biopsy-proven. However, it should be noted that: Most patients who participated in clinical trials of pioglitazone for were non-diabetic Long term safety and efficacy of pioglitazone in patients with is not established. *Not approved as a treatment for NAFLD/ Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease. AASLD, AGA, ACG Practice Guideline. Hepatology Jun;55(6): Multisociety Practice Guideline: Vitamin E & Vitamin E (α-tocopherol) 800 IU/day: Improves liver histology in non-diabetic adults with biopsy-proven Should be considered as a first-line pharmacotherapy for this patient population Until further data supporting effectiveness become available, vitamin E is not recommended to treat in: Diabetic patients NAFLD without liver biopsy cirrhosis Cryptogenic cirrhosis Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease. AASLD, AGA, ACG Practice Guideline. Hepatology Jun;55(6): Evidence: C Alcohol Use in Individuals with NAFLD and While heavy drinking is certainly deleterious, there are evolving data to suggest non-heavy drinking may have hepatic and metabolic benefits -- Liangpunsakul S, Chalasani N. Am J Gastroenterol. 2012;107(7): Practice Guideline Recommendation Patients with NAFLD should not consume heavy amounts of alcohol No recommendation can be made with regards to non-heavy consumption of alcohol by individuals with NAFLD Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease. AASLD, AGA, ACG Practice Guideline. Hepatology Jun;55(6): Cardiovascular Disease in NAFLD NAFLD is heavily enriched with cardiovascular risk factors Increased prevalence of surrogate markers of coronary artery disease Many studies have shown cardiovascular disease as the single most common cause of death in patients with NAFLD Targher G, Day CP, Bonora E. N Engl J Med. 2010;363: Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease. AASLD, AGA, ACG Practice Guideline. Hepatology Jun;55(6):
7 General Guidelines for Managing Cardiovascular Risk in NAFLD Diet low in sodium and simple sugars Unsaturated fat Increased fruits and vegetables Foods enriched with omega-3 fatty acids Caloric restriction to achieve and maintain ideal body weight Moderate to vigorous exercise for 30 to 60 minutes per day most days of the week Smoking cessation Avoidance of alcohol Statins Can Be Used Safely In Patients with NAFLD and Patients with NAFLD are important targets for statins Risk of serious hepatotoxicity from statins is very rare Patients with underlying liver disease are not at higher risk for statin hepatotoxicity Case series have shown histological improvement in Fish oil is probably the first choice to treat hypertriglyceridemia Chalasani N. Hepatology. 2005; 41(4): Lewis JH, et al. Hepatology. 2007;46: Take Home Messages Exclude competing etiologies and look for coexisting liver diseases Steatosis is hepatically benign but is progressive and can lead to cirrhosis Patients with NAFLD are at higher risk for incident type 2 diabetes and cardiovascular disease Liver biopsy can establish the diagnosis of Management of NAFLD includes managing underlying metabolic and cardiovascular risks as well as managing the liver disease Questions?
NAFLD & NASH. Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
NAFLD & NASH Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology Indiana University School of Medicine ACG Midwest Regional Course,
More informationNon-Alcoholic Steatohepatitis (NASH): What the Gastroenterologist Should Know
Non-Alcoholic Steatohepatitis (NASH): What the Gastroenterologist Should Know Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
More informationNAFLD: ACG Southern Regional Course Nashville, TN. Speaking - None
NAFLD: 2015 Naga Chalasani, MD, FACG David W. Crabb Professor of Medicine Director, Division of GI and Hepatology Indiana University School of Medicine ACG Southern Regional Course Nashville, TN Disclosures
More informationNormal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos
Fatty liver disease Its not just for big boys anymore Ken Flora, MD, FAASLD, FACG, AGAF No disclosures Common situation Normal ALT for men 30 IU/L 36% US males abnormal Normal ALT for women 20 IU/L 28%
More informationPEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE
PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE Updates on New insights into NAFLD and NASH pathophysiology New AASLD/AGA/ACG guidelines for NAFLD and NASH, as pertains to pediatrics Evidence-based
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the
More informationNAFLD: US GUIDELINES. US Guidelines for NAFLD
NAFLD: US GUIDELINES Arun J Sanyal M.D. Charles Caravati Professor of Medicine Virginia Commonwealth University School of Medicine US Guidelines for NAFLD Represents consensus amongst AGA, AASLD and ACG
More informationAt Least 1 in 5 Patients in Your Practice Have Fatty Liver
At Least 1 in 5 Patients in Your Practice Have Fatty Liver What Can You Tell Your Patients Magnus McLeod MD FRCPC Assistant Professor Dalhousie University 30-NOV-2017 NAFLD Non-Alcoholic Fatty Liver Disease
More informationPREVALENCE OF NAFLD & NASH
- - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)
More informationNONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat
More informationUpdate on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic
Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics
More informationNONALCOHOLIC FATTY LIVER DISEASE
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD, MSc Hepatology and Liver Transplantation University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Terminology Pathogenesis
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationFatty Liver Disease. Mark Thursz. Imperial College
Fatty Liver Disease Mark Thursz Imperial College Non-Alcoholic Fatty Liver Disease UK adult obesity (BMI>30) 1980: 6% [M], 8% [F]. 1997: 17% [M], 20% [F]. By 2004, 23.6% of men and 23.8% of women were
More informationNASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014
NASH : Diagnosis and investigation VII Workshop international, Curitiba, Brazil 29/08/2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France Usual diagnostic circumstances
More informationDisclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease
Smash the Nash: A practical approach to fatty liver disease Bruce D. Askey, MS, ANP-BC Associate Lecturer North Andover, MA Adult Nurse Practitioner Dept. of Hepatology/Gastroenterology Guthrie Clinic
More informationNON-ALCOHOLIC FATTY LIVER DISEASE:
NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF THE PRIMARY PROVIDER Archita P. Desai, MD Assistant Professor of Medicine University of Arizona 25 th Annual Southwestern Conference on Medicine Outline Pathophysiology
More informationEVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
More informationFATTY LIVER DISEASE (NAFLD) (NASH) A GROWING
NON ALCOHOLIC FATTY LIVER DISEASE () & NON ALCOHOLIC S T E ATO H E PAT I T I S () ADDRESSING A GROWING SILENT EPIDEMIC Prevalence of & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams
More informationThe role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
More informationNAFLD & NASH: Russian perspective
NAFLD & NASH: Russian perspective Vasily Isakov, MD, PhD Professor, Chief, Department Gastroenterology & Hepatology, Federal Research Center of nutrition, biotechnology and food safety Disclosures Received
More informationtage Percent Total & over Total & over Men Women Men Women
Paul Angulo, MD, FACG, AGAF Professor of Medicine, Section Chief of Hepatology Division i i of Digestive i Diseases and Nutrition i University of Kentucky Medical Center Lexington, KY Paul Angulo, MD University
More informationNonalcoholic Fatty Liver Disease in Children: Typical and Atypical
Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion
More informationNAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology
NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary
More informationThe Skinny On Non Alcoholic Fatty Liver Disease
The Skinny On Non Alcoholic Fatty Liver Disease UCSF Advances in Internal Medicine Monika Sarkar, MD, MAS UCSF Division of GI/Hepatology June 24th, 2015 Non Alcoholic Fatty Liver Disease: Outline Pathogenesis
More informationNon alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif
Non alcoholic fatty liver and Non alcoholic Steatohepatitis By Dr. Seham Seif Definition NAFL describe a common clinicopathological conditions characterized by significant lipid deposition in the hepatocytes
More informationFatty Liver in HIV. Richard K. Sterling, MD, MSc, FACP, FACG
Fatty Liver in HIV Richard K. Sterling, MD, MSc, FACP, FACG Professor of Medicine Chief, Section of Hepatology Director, HIV-Liver Disease Virginia Commonwealth University Liver-Related Deaths in HIV 1246
More informationNAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain
NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal
More informationNAFLD and NASH: The Not-So-New Kids on the Block
NAFLD and NASH: The Not-So-New Kids on the Block Mary E. Rinella, MD Associate Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Illinois This program is supported by an
More informationLavine, MD, PhD; 4 Anna Mae Diehl, MD; 5 Elizabeth M. Brunt, MD; 6 Kenneth Cusi, MD; 7 Michael Charlton, MD; 8 Arun J. Sanyal, MD
Page 1 of 59 The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and
More informationFatty Liver Disease A growing epidemic
Fatty Liver Disease A growing epidemic Updates in GIM for Primary Care Don C. Rockey March 9 th, 2018 Disclosures 2018 Research Funding (all to MUSC) NIH/NIDDK Actelion Pharmaceuticals Gilead Sciences
More informationNonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup
REVIEW REVIEW Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup Puneet Puri, M.B.B.S., M.D. and Arun J. Sanyal, M.B.B.S., M.D. Nonalcoholic fatty liver disease (NAFLD) is defined
More information6/28/2017. Update in NAFLD. Key Points. NAFLD: Epidemiology. US Population: million. NALFD Prevalence 25% 80 million
Update in NAFLD PHILLIP K HENDERSON, DO ASSISTANT PROFESSOR OF MEDICINE UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE INSTRUCTOR OF SURGERY, DIVISION OF TRANSPLANT SURGERY UNIVERSITY OF ALABAMA AT BIRMINGHAM
More informationAAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease
AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty
More informationEarly life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.
Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Outline Definition NAFLD and NASH Magnitude of the problem
More informationFatty liver disease: What do we know?
Fatty liver disease: What do we know? Prof. Dr. Claus Niederau Katholische Kliniken Oberhausen ggmbh St. Josef-Hospital Academic Teaching Hospital University of Duisburg-Essen NAFLD Non-Alcoholic Fatty
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease Varun Saxena, MD MAS Gastroenterology and Hepatology Kaiser Permanente South San Francisco Assistant Clinical Professor University of California San Francisco January
More informationImproving Access to Quality Medical Care Webinar Series
Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX
More informationWhat to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology
What to do about the high ALT picked up at the annual review Dr Michael Yee Consultant in Diabetes and Endocrinology Mrs DC HPC PMH Type 2 Diabetes (decades) Regular retinal screening No foot complications/neuropathy
More informationLaboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011
Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled
More informationFATTY LIVER WHAT YOU NEED TO KNOW AND WHEN TO WORRY JOHN IGOE MD GASTROENTEROLOGY NBIMU APRIL 28 TH 2017
FATTY LIVER WHAT YOU NEED TO KNOW AND WHEN TO WORRY JOHN IGOE MD GASTROENTEROLOGY NBIMU APRIL 28 TH 2017 CONFLICT OF INTEREST AND DISCLOSURES Financial Interest or Affiliation Commercial Enterprise(s)
More informationNon-alcoholic fatty liver disease: time to take note and manage. Philip Newsome Professor of Hepatology & Director of Centre for Liver Research
Non-alcoholic fatty liver disease: time to take note and manage Philip Newsome Professor of Hepatology & Director of Centre for Liver Research Disclosures Consultancy, Co-ordinating Investigator roles
More informationHEP DART 2017, Kona, Hawaii
HEP DART 2017, Kona, Hawaii Rong Yu 1, Ke Xu 1, Jing Li 1, Tong Sun 1, Shengjiang Zhang 2, Jinhua Shao 2, Jin Sun 2, Qiong He 3, Jianwen Luo 3, Cheng Wang 4, Yudong Wang 4, Jing Chen 4, Vanessa Wu 4, George
More informationDietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and
Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic
More informationALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche,
Supplemental Methods Analytical determinations ALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche, Basel, Switzerland). Glucose, triglyceride, total
More informationEASL EASD EASO Clinical practice guidelines for the management of nonalcoholic fatty liver disease.
Commentary. EASL EASD EASO Clinical practice guidelines for the management of nonalcoholic fatty liver disease. Christopher D. Byrne 1,2, Giovanni Targher 3 1 Nutrition and Metabolism, Faculty of Medicine,
More informationAssessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. IV (June. 2017), PP 49-53 www.iosrjournals.org Assessment of Liver Stiffness by Transient
More informationNonalcoholic Steatohepatitis: Evaluation and Management
Nonalcoholic Steatohepatitis: Evaluation and Management Jaideep Behari, MD, PhD Division of Gastroenterology, Hepatology, & Nutrition Fatty Liver Disease Program UPMC Center for Liver Diseases University
More informationPrevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar
Original Research Article Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar Naresh Kumar 1, Jyoti Kumar Dinkar 2*, Chandrakishore
More informationUpdate on Clinical Management
Non-Alcoholic Fatty Liver Disease Update on Clinical Management Lisa J. Yoo, D.O. Gastroenterologist Regional Gastroenterology INTRODUCTION Non-alcoholic fatty liver disease (NAFLD) is characterized by
More informationMETABOLIC SYNDROME AND HCV: FROM HCV
METABOLIC SYNDROME AND HCV: FROM THEORY TO PRACTICE HCV Steatosis Insulin resistance Arun J Sanyal M.D. Chairman, Div. of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond,
More informationNASH: WHAT YOU NEED TO KNOW
NASH: WHAT YOU NEED TO KNOW MARCELO KUGELMAS, MD, FACP SOUTH DENVER GASTROENTEROLOGY CENTER FOR DISEASES OF THE LIVER AND PANCREAS, SWEDISH MEDICAL CENTER CLINICAL ASSOCIATE PROFESSOR OF MEDICINE, UNIVERSITY
More informationIn Search of New Biomarkers for Nonalcoholic Fatty Liver Disease
REVIEW In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease Ting-Ting Chan, M.R.C.P., and Vincent Wai-Sun Wong, M.D. Nonalcoholic fatty liver disease (NAFLD) affects 15% to 40% of the general
More informationTransient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
More informationThe Liver for the Nonhepatologist
The Liver for the Nonhepatologist Michael R. Charlton, MBBS, FRCP Hepatology Director and Medical Director of Liver Transplantation Intermountain Medical Center Salt Lake City, Utah FORMATTED: 05-14-15
More informationLiver Pathology in the 0bese
Liver Pathology in the 0bese Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Ludwig et al. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
More informationNoninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD
Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis
More informationWHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH?
WHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH? Helena Cortez-Pinto Laboratório de Nutrição, FML, Serviço de Gastrenterologia, Hospital St Maria, Lisboa, Portugal EASL Governing Board:
More informationAbnormal LFTs and NAFLD. Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London
Abnormal LFTs and NAFLD Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London Does Liver Disease Matter? Mortality in England & Wales Liver-related
More informationEvaluating Obese Persons With Abnormal Liver Chemistries
Mary E. Rinella, MD, FAASLD Evaluating Obese Persons With Abnormal Liver Chemistries Postgraduate Course: Challenges in Management of Common Liver Diseases 275 1 25 year old obese Hispanic man with obesity,
More informationNAFLD, NASH, and alcoholic liver disease
NAFLD, NASH, and alcoholic liver disease Jonathan Congeni MD NAFLD, NASH, and alcoholic liver disease Disease overview Epidemiology Pathogenesis Clinical features Labs and imaging Evaluation options Focus
More informationInternal Medicine Grand Rounds University of Texas Southwestern Medical Center October 5, 2018
Internal Medicine Grand Rounds University of Texas Southwestern Medical Center October 5, 2018 Nonalcoholic Fatty Liver Disease (NAFLD) Turns 38-What Have We Learned? Jay D. Horton, M.D. This is to acknowledge
More information«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin
«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin OUTLINE NAFLD overview NAFLD and menarche NAFLD and pregnancy NAFLD and menopause Other metabolic
More informationTreatment of NASH: What Helps Beyond Weight Loss?
THE RED SECTION 821 see related editorial on page x Treatment of NASH: What Helps Beyond Weight Loss? Bubu A. Banini, MD, PhD1 and Arun J. Sanyal, MBBS, MD1 Am J Gastroenterol 2017; 112:821 824; doi: 10.1038/ajg.2017.83;
More informationPreface: Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic
NASH and NAFLD Preface: Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic David E. Bernstein xiii Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
More informationPathogenesis and Management of Non-Alcoholic Fatty Liver Disease
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/pathogenesis-management-non-alcoholic-fatty-liverdisease/8155/
More informationFirst European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health
First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st 2017 NAFLD/NASH : an expanding burden on liver health Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière,
More informationWORKSHOP. How to manage patients with NASH? Pr Jérôme Boursier Angers, France
WORKSHOP How to manage patients with NASH? Pr Jérôme Boursier Angers, France 11th Paris Hepatology Conference January 16th, 2018 Clinical case Man Man63 63years yearsold, old,referred referredby byhis
More informationNon-Alcoholic Fatty Liver Diseasean underestimated epidemic
Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Amir Shlomai MD,PhD Head, Department of Medicine D The Liver Institute Rabin Medical Center, Beilinson Hospital The IASLD semi-annual meeting-
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abetalipoproteinemia NASH and, 537 Acquired errors of metabolism NASH and, 536 537 Amiodarone steatohepatitis due to, 527 Anticonvulsant mood
More informationLa Steatosi epatica nel paziente con infezione da HIV
La Steatosi epatica nel paziente con infezione da HIV Dott. Nicola Squillace Clinica delle Malattie infettive ASST-Monza, Ospedale San Gerardo-Università di Milano-Bicocca Introduction/Background Definition
More information/ FIB4 Index , simple steatosis. FIB4 Index. FIB4 Index. FIB4 Index FIB4 Index. Sterling FIB4 Index. FIB4 Index AST AST ALT
原 著 29 34-41, 2014 FIB4 Index 1 1 1 1 2 1 1 FIB4 Index FIB4 Index cut off 2.67 2.67 12,059 FIB4 IndexFIB4 Index 2.67 / FIB4 Index AST ALT FIB4 Index 2.67 161 1.3% FIB4 Index 5 FIB4 Index 1.1 5 1.6 FIB4
More informationDisclosures. The Typical Therapeutic Pyramid $$$ The NAFLD Umbrella. The Big Question: What are the treatment options for NASH?
Disclosures I have the following relationships to disclose: Ethicon Endo Surgery Inc. Galectin Therapeutics Synageva Biopharma Raptor Pharmaceuticals I will be discussing off label use of medications in
More informationPractical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review
Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review Authors: Jennifer Gallacher, 1 *Stuart McPherson 1,2 1. Liver Unit, Newcastle Upon Tyne Hospitals NHS Trust, Freeman
More informationEASL-EASD-EASO Clinical Practice Guidelines for the management and treatment of NAFLD. Francesco Negro University of Geneva - Switzerland
EASL-EASD-EASO Clinical Practice Guidelines for the management and treatment of NAFLD Francesco Negro University of Geneva - Switzerland EASL EASD - EASO G Marchesini CP Day J-F Dufour A Canbay V Nobili
More informationNon-alcoholic fatty liver disease
Non-alcoholic fatty liver disease Link to this article online for CPD/CME credits Naveed Sattar, 1 Ewan Forrest, 2 David Preiss 1 1 BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow
More informationACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries Ashwani K. Singal, MD, MS, FACG 1, Ramon Bataller, MD, PhD, FACG 2, Joseph Ahn, MD, MS, FACG (GRADE Methodologist) 3, Patrick S. Kamath,
More informationNon-Alcoholic Fatty Liver Disease (NAFLD)
HEPATO-PANCREATO-BILIARY STOMACH CANCER PROGRAM Non-Alcoholic Fatty Liver Disease (NAFLD) Steatosis and Non-Alcoholic Steatohepatitis (NASH) Management Recommendations UCSF Fresno Department of Surgery
More informationBackground of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease
ORIGINAL ARTICLE Background of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease Takashi Wada and Mikio Zeniya Abstract Objective We investigated the distribution and characteristics of the
More informationPrognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014
Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France NASH : a severe hepatic
More informationWorld Gastroenterology Organisation Global Guidelines
WGO GUIDELINE Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Review Team, Douglas R. LaBrecque, MD, FACP (chair, USA), Zaigham Abbas, MD, MBBS, FCPS, FRCP, FRCPI, FACP, FACG, AGAF (Pakistan),
More informationM30 Apoptosense ELISA. A biomarker assay for detection and screening of NASH
M30 Apoptosense ELISA A biomarker assay for detection and screening of NASH NASH A Global Disease In the Western countries, Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common liver disease, strongly
More informationNon alcoholic fatty liver disease and atherosclerosis Raul Santos, MD
Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD Sao Paulo Medical School Hospital Sao Paulo, Brazil Disclosure Honoraria received for consult and/or speaker : Astra Zeneca, Amgen,
More informationCriteria for Dx of NASH NONALCOHOLIC STEATOHEPATITIS. Liver Ultrasound Report. Presenter Disclosure Information. Definition of NASH
1 1:45 pm NASH: Burgeoning Epidemic SPEAKER Sanjiv Chopra, MD, MACP Presenter Disclosure Information The following relationships exist related to this presentation: Sanjiv Chopra, MD, MACP: No financial
More informationAASLD Immune tolerant phase HBV NAFLD diagnostic HCC
AASLD 2016 Immune tolerant phase HBV NAFLD diagnostic HCC Immune tolerant 3 Modified from Chan HLY and Wong VWS. Hepatitis B. In Zakim and Boyers s Hepatology 2012 2015 AMERICAN ASSOCIATION FOR THE S1T6UDY
More informationThe Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases
AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES PRACTICE GUIDANCE HEPATOLOGY, VOL. 67, NO. 1, 2018 The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American
More informationDrug-induced hepatotoxicity is a well-recognized adverse. Incidence of Statin Hepatotoxicity in Patients With Hepatitis C
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:902 907 Incidence of Statin Hepatotoxicity in Patients With Hepatitis C SHIRIN KHORASHADI,* NOELLE K. HASSON,* and RAMSEY C. CHEUNG, *Pharmacy Service, and
More informationThe Liver for the Nonhepatologist
The Liver for the Nonhepatologist Michael R. Charlton, MBBS, FRCP Professor of Medicine University of Chicago Chicago, Illinois Overview Initial assessment of liver disease How do you diagnose cirrhosis?
More informationThe role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases
RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment
More informationScreening cardiac patients for advanced liver disease
HKASLD 30 th ASM and International Symposium on Hepatology 2017 Screening cardiac patients for advanced liver disease 5 Nov 2017 Dr. Lau Yue Leung Joulen Pamela Youde Nethersole Eastern Hospital NAFLD
More informationThe effect of aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with non-alcoholic fatty liver disease
Gastroenterology and Hepatology From Bed to Bench. 2013 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE The effect of aerobic exercise on serum level of liver enzymes
More informationInvestigating general liver disease/transaminitis
BHIVA Autumn Conference London 14 October 2016 Investigating general liver disease/transaminitis Emmanuel A. Tsochatzis Senior Clinical Lecturer and Consultant Hepatologist Institute for Liver and Digestive
More informationParis Hepatology Conference PROGNOSIS OF NASH
Paris Hepatology Conference PROGNOSIS OF NASH Palais des Congrès Monday 15th January 2018 14:45-15:00 PHC 2018 - www.aphc.info Driven to care Disclosures Advisory committees Speaking and teaching Research
More informationNonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse
Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse National Institute of Diabetes and Digestive and Kidney Diseases NATIONAL INSTITUTES OF HEALTH Nonalcoholic steatohepatitis
More informationWhy to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?
Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Stephen D Ryder Nottingham University Hospitals NHS Trust and Biomedical research Unit What are we currently
More informationManaging abnormal LFTs in Primary care
Managing abnormal LFTs in Primary care Summary guideline, April 2015 Sally Hull, Lucy Carter Managing abnormal LFTs in Primary care Draft guideline written by Dr Sally Hull and Dr Lucy Carter at CEG, with
More informationNon-alcoholic fatty liver disease: when to intervene and with what
CME HEPATOLOGY Clinical Medicine 2015 Vol 15, No 2: 186 90 Non-alcoholic fatty liver disease: when to intervene and with what Authors: Nwe Ni Than A and Philip N Newsome B ABSTRACT Non-alcoholic fatty
More informationCriteria for Dx of NASH NONALCOHOLIC STEATOHEPATITIS. Presenter Disclosure Information. Definition of NASH
9:45 10:30 am NASH: Burgeoning Epidemic SPEAKER Sanjiv Chopra, MD, MACP Presenter Disclosure Information The following relationships exist related to this presentation: Sanjiv Chopra, MD, MACP: No financial
More information